Seeking Alpha EN

bioAffinity Technologies GAAP EPS of -$8.66, revenue of $6.2M

Mar 13, 2026 &03151313202631; 19:15 UTC seekingalpha.com Trending 3/5

Read original on seekingalpha.com ↗

↘

Negative for markets

Sentiment score: -75/100

High impact Immediate effect (hours)

WHAT THIS MEANS

bioAffinity Technologies reported a significant GAAP loss of -$8.66 per share with revenue of $6.2M, indicating substantial operational challenges and negative profitability. The company is burning cash at a concerning rate relative to its revenue generation, suggesting potential liquidity concerns ahead.

AI CONFIDENCE

85% Very high

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↓

BIAF

BIAFStock

Expected to decline

Massive EPS loss of -$8.66 with minimal revenue of $6.2M indicates severe unprofitability and cash burn concerns

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Avoid or reduce exposure to BIAF. The company's massive losses relative to minimal revenue suggests significant financial distress. Monitor for potential dilutive financing or restructuring announcements that could further pressure shareholders.

KEY SIGNALS

Extreme negative EPSLow revenue relative to lossesCash burn riskPotential going concern issuesLack of profitability path visibility

SECTORS INVOLVED

HealthcareBiotechnologyMedical Devices

Analysis generated on Mar 16, 2026 at 13:26 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Seeking Alpha. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

bioAffinity Technologies GAAP EPS of -$8.66, revenue of $6.2M

RELATED INTELLIGENCE